Science, Industry, and You
By Pat Racimora on May 18, 2009 at 9:30 AM in Current Affairs, Health Care
Biomedical researchers are under no ethical obligation to find a cure for every physical affliction. That goal remains unreachable by even the best scientsts. However, they are obligated to hold the patients’ welfare paramount and to minimize every risk possible.
It was with great concern, then, that I read a press release of an article due to be published next month in the scholarly journal Cancer. The findings are upsetting, especially for anyone who is struggling with a cancer diagnosis within their circle of loved ones or themselves.
Nearly one-third of cancer research published in high-impact journals disclosed a conflict of interest, according to a new study from researchers at the University of Michigan Comprehensive Cancer Center.
The most frequent type of conflict was industry funding of the study, which was seen in 17 percent of papers. Twelve percent of papers had a study author who was an industry employee.
Up front it is important to point out that it is unethical to fail to disclose a conflict of interest, and that is not what is at issue here. Rather, the question is when a researcher is being paid by an entity that clearly favors a given outcome—that is, their drug or treatment will work better than anything else on the market—can that researcher remain 100% objective?
The most stunning finding with the University of Michigan’s analysis of over 1,500 cancer studies published in prestigious journals is that randomized trials reported by researchers who had a conflict of interest were more likely to have positive findings.
Aside from outright data fabrication (and no one is making such an allegation here), other more subtle sources of conscious or unconscious bias may be operating. The study design itself may contain a flaw that will favor a particular outcome. For example, perhaps sicker patients end up in the control group, making it more likely to get positive results for the experimental treatment. Researchers may be able to rationalize dropping data that would have remained in the final analysis had it been processed objectively. Perhaps studies with unwanted findings do not get submitted for publication, so no one ever knows of a negative outcome.
My friend, Dr. K., who sent me this article, also added his moving comment about what this study means to you and me.
When you think of people struggling with cancer and of all their relatives and loved ones, often riding a roller coaster of good and bad news, not knowing when and if the cancer will take their life, this kind of business is hard to understand in light of how it may be a powerfully confounding variable in the research.
The University of Michigan study suggests that biomedical research would be better funded and directed by sources other than an industry that has a stake in how the research turns out. Yet where such funds would come from any time soon is unclear. Nevertheless, my cartoon suggests an unhealthy alliance that impacts on medicine, cancer patients, and ultimately our society.























